

Synthetic Blood Penetration Resistance GLP Report

Test Article:

AntiVirus - Respilon

LOT: 20160601

Study Number:

906437-S01

Study Received Date:

25 Jul 2016

Test Procedure(s): Standard Test Protocol (STP) Number: STP0012 Rev 06

Summary: This procedure was performed to evaluate surgical facemasks and other types of protective clothing materials designed to protect against fluid penetration. The purpose of this procedure is to simulate an arterial spray and evaluate the effectiveness of the test article in protecting the user from possible exposure to blood and other body fluids. The distance from the target area surface to the tip of the cannula is 30.5 cm. A test volume of 2 mL of synthetic blood was employed using the targeting plate method.

This test method was designed to comply with ASTM F1862 and ISO 22609 (as referenced in EN 14683:2014) with the following exception. ISO 22609 requires testing to be performed in an environment with a temperature of 21 ± 5°C and a relative humidity of 85 ± 10%. Instead, testing was performed at ambient conditions within one minute of removal from the environmental chamber held at those parameters.

All test method acceptance criteria were met.

Number of Test Articles Tested: 32

Number of Test Articles Passed: 31

Test Side: Outside

Pre-Conditioning: Minimum of 4 hours at 21 ± 5°C and 85 ± 5% relative humidity (RH)

Test Conditions: 20.1°C and 23% RH

Results: Per ASTM F1862 and ISO 22609, an acceptable quality limit of 4.0% is met for a normal single sampling plan when ≥29 of 32 test articles show passing results.

Test Pressure:

120 mm Hq

-				
les	tΑ	rticle	Nui	mber

Synthetic Blood Penetration

1-17, 19-32

None Seen

18

Yes

Test Method Acceptance Criteria: The output of synthetic blood through the targeting hole before and after every 16 test articles must be within 2% (± 0.04 g) of the theoretical output of 2 mL.

Study Director

Brandon L. Williams

P.O. Box 571830 | Murray, UT 84157-1830 U.S.A · 6280 South Redwood Road | Salt Lake City, UT 84123-6600 U.S.A.

www.neisonlabs.com · Telephone 801 290 7500 · Fax 801 290 7998 · sales@neisonlabs.com

FRT0012-0002 Rev 7 Page 1 of 3



Procedure: A clean cannula was fixed onto the front of the valve and the reservoir was filled with synthetic blood. The reservoir pressure and timer were set to allow a differential weight of 95-102%. This was achieved by setting the valve timer to 0.5 seconds and 1.5 seconds, collecting and weighing the amount of fluid before and after the targeting hole, and then calculating the weight differences for the deliveries. After the reservoir pressure and timer duration had been adjusted, the 2 mL spray was verified by dispensing three spurts in a row through the targeting hole into a graduated cylinder and weighing. After every 16 specimens, synthetic blood was delivered into a graduated cylinder and weighed to ensure the test apparatus was still delivering 2 mL of synthetic blood.

Each test article was tested within one minute of removal from the conditioning chamber. The facemask was mounted on the specimen holding fixture and positioned 305 mm (12 in) from the cannula. The mask was then subjected to the 2 mL volume spray, which moved from the cannula in a horizontal path perpendicular to the facemask. This procedure used a targeting hole that blocked the initial, high-pressure portion of the synthetic blood stream and allowed only the fluid traveling at the target velocity to hit the center of the mask. Each test article was observed for penetration within 10 seconds of dispensing the synthetic blood against the target area.



Quality Assurance Statement

Compliance Statement: The test was conducted in accordance with the USFDA (21 CFR Parts 58, 210, 211, and 820) Regulations. This final report reflects the raw data.

Activity	Date 04 Oct 2016	
Study Initiation		
Phase Inspected by Quality Assurance: Penetration Test	10 Oct 2016	
Audit Results Reported to Study Director	13 Oct 2016	
Audit Results Reported to Management	14 Oct 2016	

Scientists	Title		
Adam Meese		Supervisor	
Brandon Williams		Study Director	

Data Disposition: The study plan, raw data and final report from this study are archived at Nelson Laboratories, LLC or an approved off-site location.

Quality Assurance

Date

130ct 2016